Sun Pharma Signs a License Agreement with Hikma for Ilumya (tildrakizumab) in MENA Regions

 Sun Pharma Signs a License Agreement with Hikma for Ilumya (tildrakizumab) in MENA Regions

Sun Pharma Launches Drizalma Sprinkle (duloxetine delayed-release capsules) for Neuro-Psychiatric and Pain Disorders in the US

Shots:

  • SunPharma to receive upfront and milestones for licensing its product to Hikma and will supply Ilumya.  Hikma will be responsible for the registration and commercialization of the product in all MENA markets
  • Hikma’s presence in the MENA region will enable access to a new treatment option for people who are unable to manage their moderate-to-severe plaque psoriasis
  • Ilumya (tildrakizumab) is a humanized lgG1/k mAb designed to selectively bind to the p19 subunit of IL-23 and inhibit its interaction with the IL-23 receptor and has received the US FDA’s approval in 2018

Click here to read full press release/ article | Ref: Sun Pharma | Image: Pharmaworld

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post